- Home
- IRWD vs NTHI Comparison
IRWD vs NTHI Comparison
Compare IRWD & NTHI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IRWD
- NTHI
- Stock Information
- Founded
- IRWD 1998
- NTHI 2008
- Country
- IRWD United States
- NTHI United States
- Employees
- IRWD N/A
- NTHI N/A
- Industry
- IRWD Biotechnology: Pharmaceutical Preparations
- NTHI Biotechnology: Pharmaceutical Preparations
- Sector
- IRWD Health Care
- NTHI Health Care
- Exchange
- IRWD Nasdaq
- NTHI Nasdaq
- Market Cap
- IRWD 111.2M
- NTHI 110.9M
- IPO Year
- IRWD 2010
- NTHI N/A
- Fundamental
- Price
- IRWD $1.03
- NTHI $5.12
- Analyst Decision
- IRWD Buy
- NTHI
- Analyst Count
- IRWD 5
- NTHI 0
- Target Price
- IRWD $4.94
- NTHI N/A
- AVG Volume (30 Days)
- IRWD 1.5M
- NTHI 320.0K
- Earning Date
- IRWD 08-07-2025
- NTHI 01-01-0001
- Dividend Yield
- IRWD N/A
- NTHI N/A
- EPS Growth
- IRWD N/A
- NTHI N/A
- EPS
- IRWD N/A
- NTHI N/A
- Revenue
- IRWD $308,519,000.00
- NTHI $79,990.00
- Revenue This Year
- IRWD N/A
- NTHI N/A
- Revenue Next Year
- IRWD N/A
- NTHI N/A
- P/E Ratio
- IRWD N/A
- NTHI N/A
- Revenue Growth
- IRWD N/A
- NTHI 13.52
- 52 Week Low
- IRWD $0.53
- NTHI $3.20
- 52 Week High
- IRWD $5.21
- NTHI $25.00
- Technical
- Relative Strength Index (RSI)
- IRWD 63.45
- NTHI N/A
- Support Level
- IRWD $0.81
- NTHI N/A
- Resistance Level
- IRWD $1.16
- NTHI N/A
- Average True Range (ATR)
- IRWD 0.11
- NTHI 0.00
- MACD
- IRWD 0.02
- NTHI 0.00
- Stochastic Oscillator
- IRWD 70.45
- NTHI 0.00
About IRWD Ironwood Pharmaceuticals Inc.
Ironwood Pharmaceuticals Inc is a specialty and generic drug manufacturing company that operates a human therapeutics segment. The company is focused on advancing product opportunities in areas of large unmet need, including irritable bowel syndrome with constipation, chronic idiopathic constipation, hyperuricemia associated with uncontrolled gout, uncontrolled gastroesophageal reflux disease, and vascular and fibrotic diseases. The company considers collaborative licenses, commercial agreements, and acquisition investment to be potential components of its operational growth plan for expanding its research, development, manufacturing, and marketing capabilities.
About NTHI NeOnc Technologies Holdings Inc. Common Stock
NeOnc Technologies Holdings Inc. is the developer of a novel molecular technology that provides enhanced targeted delivery of technologies for treating central nervous system diseases. The company product includes NEO100, which commenced Phase 2a clinical trials, which is used for treating glioblastoma, and has Orphan Drug and Fast Track designation from the United States Food and Drug Administration ("FDA").